BRPI0414924A - ligantes de tim-3 e seus métodos - Google Patents
ligantes de tim-3 e seus métodosInfo
- Publication number
- BRPI0414924A BRPI0414924A BRPI0414924-6A BRPI0414924A BRPI0414924A BR PI0414924 A BRPI0414924 A BR PI0414924A BR PI0414924 A BRPI0414924 A BR PI0414924A BR PI0414924 A BRPI0414924 A BR PI0414924A
- Authority
- BR
- Brazil
- Prior art keywords
- tim
- methods
- domain
- polypeptide
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
"LIGANTES DE TIM-3 E SEUS MéTODOS". A invenção se refere a polipeptídeos isolados e a ácidos que codificam polipeptídeos que compreendem um dominio de IgV de tim-3 e um domínio intracelular de tim-3, não compreendendo o polipeptídeo nem um domínio de mucina de tim-3 nem um domínio de transmembrana de tim-3. Além disso, a invenção se refere a métodos de modulação de respostas imunes em um paciente, métodos estes que compreendem a administração ao paciente de uma quantidade terapeuticamente efetiva de um agente que modula a atividade de tim-3. As respostas imunes incluem, sem limitação, tolerância imune, tolerância a transplante, respostas a Th2 e a Th2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50831903P | 2003-10-03 | 2003-10-03 | |
PCT/US2004/032749 WO2005033144A2 (en) | 2003-10-03 | 2004-10-04 | Tim-3 polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0414924A true BRPI0414924A (pt) | 2006-11-07 |
Family
ID=34421718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0414924-6A BRPI0414924A (pt) | 2003-10-03 | 2004-10-04 | ligantes de tim-3 e seus métodos |
Country Status (13)
Country | Link |
---|---|
US (3) | US8329660B2 (pt) |
EP (1) | EP1685159B1 (pt) |
JP (3) | JP2008500013A (pt) |
KR (1) | KR20060089732A (pt) |
CN (1) | CN1902227A (pt) |
BR (1) | BRPI0414924A (pt) |
CA (1) | CA2541006C (pt) |
HK (1) | HK1096692A1 (pt) |
IL (1) | IL174510A (pt) |
MX (1) | MXPA06003686A (pt) |
RU (1) | RU2006114694A (pt) |
WO (1) | WO2005033144A2 (pt) |
ZA (1) | ZA200602693B (pt) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3020413A1 (en) | 2002-01-30 | 2016-05-18 | The Brigham and Women's Hospital, Inc. | Compositions and methods related to TIM-3, a TH1-specific cell surface molecule |
TW200539890A (en) * | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
WO2008013082A1 (fr) * | 2006-07-25 | 2008-01-31 | Galpharma Co., Ltd. | Conjugué galectine 9/polymère |
JP2010510223A (ja) * | 2006-11-15 | 2010-04-02 | サ ブリガム アンド ウィメンズ ホスピタル インコーポレーティッド | Tim−3調節物質の治療的使用 |
JP2011500730A (ja) * | 2007-10-26 | 2011-01-06 | ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント | Tim−3を用いた治療および診断方法 |
EP4160212B1 (en) | 2008-01-15 | 2024-04-17 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
US20110059106A1 (en) * | 2008-01-29 | 2011-03-10 | Brigham And Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
JP5569946B2 (ja) * | 2009-01-26 | 2014-08-13 | 国立大学法人 岡山大学 | 免疫抑制剤および自己免疫疾患の予防および治療剤 |
US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
EP2879709B1 (en) * | 2012-07-31 | 2020-01-08 | The Brigham and Women's Hospital, Inc. | Modulation of the immune response |
US20140287933A1 (en) * | 2013-03-14 | 2014-09-25 | Savannah Tobin | METHODS FOR MEASURING FEL d 1 CAT ALLERGEN |
WO2015003114A1 (en) | 2013-07-05 | 2015-01-08 | University Of Washington Through Its Center For Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
US10144778B2 (en) * | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
FR3021970B1 (fr) | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs |
WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
CA2965960A1 (en) * | 2014-10-27 | 2016-05-06 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
GB201419094D0 (en) * | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
PT3215532T (pt) * | 2014-11-06 | 2019-12-18 | Hoffmann La Roche | Anticorpos anti-tim3 e métodos de utilização |
EP4141032A1 (en) | 2014-11-20 | 2023-03-01 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
CN104592388B (zh) * | 2015-03-02 | 2017-05-31 | 中国人民解放军总医院 | 一种抗人Tim‑3的单克隆抗体的抗原结合部分 |
US10786547B2 (en) | 2015-07-16 | 2020-09-29 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
BR112018006578A2 (pt) | 2015-10-01 | 2018-12-26 | Heat Biologics, Inc. | composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas |
CN105348393A (zh) * | 2015-11-17 | 2016-02-24 | 中国人民解放军第四军医大学 | 一种偶联抗体的合成、检测方法和应用 |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
JP6987424B2 (ja) | 2016-05-11 | 2022-01-05 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを洗浄および/または消毒する方法 |
SG11201810023QA (en) | 2016-05-27 | 2018-12-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
TWI780057B (zh) | 2016-07-14 | 2022-10-11 | 美商必治妥美雅史谷比公司 | 針對tim3之抗體及其用途 |
WO2018129261A1 (en) | 2017-01-05 | 2018-07-12 | Brown University | Methods and compositions relating to anti-chi3l1 antibody reagents |
US11332509B2 (en) | 2017-02-27 | 2022-05-17 | Shattuck Labs, Inc. | Methods of making and using extracellular domain-based chimeric proteins |
CN111148760A (zh) | 2017-02-27 | 2020-05-12 | 卡拉斯医疗有限公司 | 抗体构建体和治疗癌症的方法 |
CA3060935A1 (en) | 2017-05-01 | 2018-11-08 | The Children's Medical Center Coporation | Methods and compositions relating to anti-pd1 antibody reagents |
CA3064023A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
EP3658172A4 (en) * | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | CANCER TREATMENT BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
EP3758732A1 (en) | 2018-02-27 | 2021-01-06 | Leidos, Inc. | Pd-1 peptide inhibitors |
WO2019191406A1 (en) * | 2018-03-29 | 2019-10-03 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric tim-3 fusion protein |
CN109180816B (zh) * | 2018-09-17 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人tim-3抗体及其用途 |
US20210353715A1 (en) * | 2018-09-20 | 2021-11-18 | Mandalmed, Inc. | Methods and compositions for preventing, treating, and reversing liver fibrosis |
CN110655566B (zh) * | 2018-10-25 | 2021-06-18 | 浙江大学 | 可溶性Tim-3重组蛋白及其突变型蛋白的制备和应用 |
CN109666698B (zh) * | 2018-12-29 | 2023-03-07 | 杭州科兴生物科技有限公司 | 一种基于Tim-3/Galectin-9阻断功能及其生物效应的药物快速筛选方法 |
CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
CA3141162A1 (en) | 2019-05-22 | 2020-11-26 | Leidos, Inc. | Lag3 binding peptides |
AU2021283353A1 (en) | 2020-06-04 | 2023-02-02 | Leidos, Inc. | Immunomodulatory compounds |
WO2022020745A1 (en) * | 2020-07-23 | 2022-01-27 | Emory University | Galectin-9 specific binding agents for use in treating cancer |
AU2021316230A1 (en) | 2020-07-31 | 2023-03-16 | Leidos, Inc. | LAG3 binding peptides |
AU2021361844A1 (en) | 2020-10-12 | 2023-06-15 | Leidos, Inc. | Immunomodulatory peptides |
WO2022216942A1 (en) | 2021-04-07 | 2022-10-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US6455685B1 (en) * | 1995-03-03 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
US6066322A (en) * | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
US20030069196A1 (en) * | 1995-03-03 | 2003-04-10 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
WO1998015624A1 (en) | 1996-10-09 | 1998-04-16 | Human Genome Sciences, Inc. | Galectin 8, 9, 10 and 10sv |
US6027916A (en) * | 1996-10-09 | 2000-02-22 | Human Genome Sciences, Inc. | Galectin 9 and 10SV Polynucleotides |
US6190909B1 (en) * | 1997-04-17 | 2001-02-20 | Millennium Pharmaceuticals, Inc. | TH2-specific gene |
CA2317702A1 (en) | 1998-01-07 | 1999-07-15 | Human Genome Sciences, Inc. | 36 human secreted proteins |
WO2001012215A2 (en) * | 1999-08-13 | 2001-02-22 | The Rockefeller University | Protective antigen of epstein barr virus |
CA2392398A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
AU2001243142A1 (en) | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US6288217B1 (en) * | 2000-08-18 | 2001-09-11 | Lexmark International, Inc. | Black azo dyes |
WO2002081517A2 (en) | 2001-01-19 | 2002-10-17 | Curagen Corporation | Novel polypeptides and nucleic acids encoded thereby |
EP1406653A4 (en) * | 2001-06-29 | 2005-05-04 | Univ Leland Stanford Junior | T-LYMPHOCYTE REGULATORY GENES AND METHODS OF USE |
US7838220B2 (en) | 2001-06-29 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes associated with immune disease |
EP3020413A1 (en) * | 2002-01-30 | 2016-05-18 | The Brigham and Women's Hospital, Inc. | Compositions and methods related to TIM-3, a TH1-specific cell surface molecule |
DE10213762A1 (de) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Int | Neues costimulierendes Molekül und dessen Verwendung |
EP2025345A1 (en) | 2002-12-30 | 2009-02-18 | Biogen Idec MA Inc. | KIM-1 antagonists and use to modulate immune system |
US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
US20050276756A1 (en) * | 2004-03-24 | 2005-12-15 | Hoo William S | Compositions as adjuvants to improve immune responses to vaccines and methods of use |
-
2004
- 2004-10-04 CN CNA2004800361589A patent/CN1902227A/zh active Pending
- 2004-10-04 KR KR1020067006319A patent/KR20060089732A/ko not_active Application Discontinuation
- 2004-10-04 US US10/958,169 patent/US8329660B2/en active Active
- 2004-10-04 WO PCT/US2004/032749 patent/WO2005033144A2/en active Application Filing
- 2004-10-04 BR BRPI0414924-6A patent/BRPI0414924A/pt not_active Application Discontinuation
- 2004-10-04 JP JP2006534252A patent/JP2008500013A/ja active Pending
- 2004-10-04 CA CA2541006A patent/CA2541006C/en not_active Expired - Fee Related
- 2004-10-04 EP EP04794190A patent/EP1685159B1/en active Active
- 2004-10-04 MX MXPA06003686A patent/MXPA06003686A/es not_active Application Discontinuation
- 2004-10-04 RU RU2006114694/13A patent/RU2006114694A/ru not_active Application Discontinuation
-
2006
- 2006-03-23 IL IL174510A patent/IL174510A/en not_active IP Right Cessation
- 2006-03-31 ZA ZA2006/02693A patent/ZA200602693B/en unknown
-
2007
- 2007-02-02 HK HK07101287.3A patent/HK1096692A1/xx not_active IP Right Cessation
-
2011
- 2011-08-15 JP JP2011177551A patent/JP5474009B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-06 US US13/670,096 patent/US20130183688A1/en not_active Abandoned
-
2013
- 2013-10-09 JP JP2013211909A patent/JP2014039558A/ja active Pending
-
2014
- 2014-04-29 US US14/264,791 patent/US9346876B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL174510A0 (en) | 2006-08-01 |
CA2541006C (en) | 2015-02-17 |
HK1096692A1 (en) | 2007-06-08 |
EP1685159B1 (en) | 2012-08-01 |
US8329660B2 (en) | 2012-12-11 |
JP5474009B2 (ja) | 2014-04-16 |
CA2541006A1 (en) | 2005-04-14 |
RU2006114694A (ru) | 2007-11-10 |
JP2014039558A (ja) | 2014-03-06 |
US9346876B2 (en) | 2016-05-24 |
JP2012006959A (ja) | 2012-01-12 |
WO2005033144A2 (en) | 2005-04-14 |
CN1902227A (zh) | 2007-01-24 |
US20130183688A1 (en) | 2013-07-18 |
EP1685159A2 (en) | 2006-08-02 |
WO2005033144A3 (en) | 2005-06-16 |
MXPA06003686A (es) | 2007-03-01 |
IL174510A (en) | 2011-06-30 |
US20050191721A1 (en) | 2005-09-01 |
ZA200602693B (en) | 2009-08-26 |
JP2008500013A (ja) | 2008-01-10 |
US20140348842A1 (en) | 2014-11-27 |
KR20060089732A (ko) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0414924A (pt) | ligantes de tim-3 e seus métodos | |
EP0713493A4 (en) | PRODUCTION OF HUMAN HEMOGLOBIN IN TRANSGENIC PIGS | |
TW200711657A (en) | Pharmaceutical composition comprising botulinum toxin and recombinant human serum albumin | |
EP0590076A4 (en) | Production of human hemoglobin in transgenic pigs | |
IL156842A0 (en) | Combined use of factor vii polypeptides and factor ix polypeptides | |
ATE531382T1 (de) | Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen | |
MY137181A (en) | Pulmonary administration of chemically modified insulin | |
CY1110727T1 (el) | Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση | |
PT1171143E (pt) | Extracto peptidico de tremoco e composicao farmaceutica ou cosmetica ou nutraceutica compreendendo o referido extracto | |
MXPA02004933A (es) | Composiciones cosmeticas conteniendo extracto de garbanzo y retinoides. | |
DE60012301D1 (de) | Lipoproteinkomplexe und zusammensetzungen, die diese enthalten | |
WO2002056708A3 (de) | Zubereitung zur verbesserung der nahrungsverwertung | |
HUP0100539A2 (hu) | D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására | |
CY1108138T1 (el) | Χρησιμοποιηση λουπινοκονγλουτινης δια την θεραπευτικη αγωγη διαβητου τυπου ιι | |
BR0308713A (pt) | Co-esférula de dha e alecrim, e métodos de uso | |
ATE348602T1 (de) | Nanoteilchen zur verabreichung von wirkstoffen, verfahren zur herstellung dieser teilchen und diese enthaltende zusammensetzung | |
HUP0304077A2 (hu) | A bőr öregedése elleni gyógyászati és kozmetikai készítmények | |
ATE313562T1 (de) | Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins | |
HUP0401593A2 (hu) | A PTX3 hosszú pentraxin alkalmazása gyógyhatású készítmény előállítására autoimmun betegségek megelőzésére és kezelésére | |
WO2002062843A3 (en) | Modified erythropoietin (epo) with reduced immunogenicity | |
ATE515258T1 (de) | Mukosales verabreichungssytem | |
BRPI0410761A (pt) | uso de leucina, e, composição para administração entérica a pacientes | |
ATE339446T1 (de) | Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität | |
ATE214935T1 (de) | Robinia pseudoacacia lektin und seine verwendungen | |
ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |